Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial

被引:19
作者
Bago, Josip [1 ]
Majstorovic, Karolina [1 ]
Belosic-Halle, Zeljka [1 ]
Kucisec, Nastja [2 ]
Bakula, Vinko [1 ]
Tomic, Monika [3 ]
Bago, Petra [1 ]
Troskot, Rosana [1 ]
机构
[1] Clin Hosp Sveti Duh, Internal Med Clin, Dept Gastroenterol, Zagreb, Croatia
[2] Clin Hosp Sveti Duh, Dept Microbiol, Zagreb, Croatia
[3] Univ Hosp Mostar, Internal Med Clin, Dept Gastroenterol, Mostar, Bosnia & Herceg
来源
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS | 2010年 / 9卷
关键词
Pylorus Infection; Levofloxacin; Moxifloxacin; Lansoprazole; Pylorus Eradication;
D O I
10.1186/1476-0711-9-13
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Introduction: Antibiotic resistance decreases success of Helicobacter pylori (Hp) eradication. Recently published results show low rate of resistance and better compliance with moxifloxacin based regiments. Aims&methods: Whether 7 days moxifloxacin with lansoprasole and amoxycillin can be compared with 10 days moxifloxacin with lansoprasole and amoxycillin according to moxifloxacin resistance. Patients with non-ulcer dyspepsia who had culture and histology positive Hp infection (n = 150) were randomly assigned into two groups. The first group (n = 75) received moxifloxacin 400 mg/d during 7 days and the other (n = 75) received moxifloxacin 400 mg/d during 10 days. All patients received amoxycillin 1 g twice daily, lansoprasole 30 mg twice daily. All Hp cultures were tested for sensitivity to moxifloxacin. Results: 138 patients (92%) completed the study, 68 in the first group and 70 in the second. Eradication rates were 84% (57/68) and 76% (57/75) in the 7 days moxifloxacin group and 90% and 84% in the second group (63/70, 63/75) according to the PP and ITT analysis; p = n.s. Among 129 patients (86% of study group), 6% of strains were primary resistant to moxifloxacin. Eradication of moxifloxacin sensitive/resistant strains was 98%/66%, p < 0.05 Conclusion: According to our results we recommend 7 days moxiflixacin based triple therapy.
引用
收藏
页数:6
相关论文
共 28 条
  • [1] 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity
    Antos, D
    Schneider-Brachert, W
    Bästlein, E
    Hänel, C
    Haferland, C
    Buchner, M
    Meier, E
    Trump, F
    Stolte, M
    Lehn, N
    Bayerdörffer, E
    [J]. HELICOBACTER, 2006, 11 (01) : 39 - 45
  • [2] Bago J, 2002, WIEN KLIN WOCHENSCHR, V114, P448
  • [3] Hohe eradikationsrate von H-Pylori mit moxifloxacin-basierter therapie:: Eine randomisierte kontrollierte studie
    Bago, Petra
    Vcev, Aleksandar
    Tomic, Monika
    Rozankovic, Marjan
    Marusic, Marinko
    Bago, Josip
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2007, 119 (11-12) : 372 - 378
  • [4] Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium
    Bogaerts, Pierre
    Berhin, Catherine
    Nizet, Henri
    Glupczynski, Youri
    [J]. HELICOBACTER, 2006, 11 (05) : 441 - 445
  • [5] Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection
    Cammarota, G
    Cianci, R
    Cannizzaro, O
    Cuoco, L
    Pirozzi, G
    Gasbarrini, A
    Armuzzi, A
    Zocco, MA
    Santarelli, L
    Arancio, F
    Gasbarrini, G
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) : 1339 - 1343
  • [6] Update on fluoroquinolone resistance in Helicobacter pylori:: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility
    Cattoir, Vincent
    Nectoux, Juliette
    Lascols, Christine
    Deforges, Lionel
    Delchier, Jean-Charles
    Megraud, Francis
    Soussy, Claude-James
    Cambau, Emmanuelle
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 (04) : 389 - 396
  • [7] Della Monica P, 2002, ALIMENT PHARM THER, V16, P1269
  • [8] Levofloxacin based regimens for the eradication of Helicobacter pylori
    Di Caro, S
    Zocco, MA
    Cremonini, F
    Candelli, M
    Nista, EC
    Bartolozzi, F
    Armuzzi, A
    Cammarota, G
    Santarelli, L
    Gasbarrini, A
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2002, 14 (12) : 1309 - 1312
  • [9] Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication
    Di Caro, S
    Ojetti, V
    Zocco, MA
    Cremonini, F
    Bartolozzi, F
    Candelli, M
    Lupascu, A
    Nista, EC
    Cammarota, G
    Gasbarrini, A
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (03) : 527 - 532
  • [10] Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori:: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer
    Ducóns, JA
    Santolaria, S
    Guirao, R
    Ferrero, M
    Montoro, M
    Gomollón, F
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (06) : 775 - 780